New hope for lung cancer patients who stopped responding to standard treatment
Disease control
Completed
This study tested whether adding a new drug called cabozantinib to an existing lung cancer drug (erlotinib) could help patients whose cancer had started growing again after initially responding to erlotinib alone. The trial involved 92 adults with advanced non-small cell lung can…
Phase: PHASE1, PHASE2 • Sponsor: Exelixis • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC